definiens: means purified and isolated extracellular vesicle compositions, whether obtained from CCM or any other means ; provi ded, that extracellular vesicle compositions from or based on any [COMPANY] extracel lular matrix shall be excluded from unless such compositions would be c overed by at least one of the claims of U.S. Patent Application No . 62/623,851, a s filed January 30, 2018 . ” c. Section 1.16 of the License Agreement is hereby amended and restated in its entirety to read as follows : means any product, other than a Product introduced by Allergan or its Affiliates, that contains CCM or si milar technology as an ingredient that is marketed in the Field of Use . For the avoid ance of doubt, Exosome is not a to CCM for defining a d. Section 1.17 of the License Agreement is hereby amended and restated in its entirety to read as follows : means any adaptation, change, redesign, modificati on, invention, discovery, enhancement or development co nceived, reduced to practice, developed or made after the Effective Date and ( i ) incorporated into a Product, ( ii ) made with respect to the specifications, the r aw materials or the method or process of manufacture or production of a Product, including, but not limited to, any product which uses CCM or similar technology and pe rforms the same function as a Product, ( iii ) incorporating, utilizing, or develop ed utilizing, Technical Information related to CCM to create a Similar Product, ( iv ) re quiring the practice of an invention claimed in the Patent Rights related to CCM to crea te a Similar Product, or ( v ) serves to create a Similar Product . Notwithstanding the fo regoing, will not include any intellectual property, invention, disco very or enhancement or development conceived and reduced to practice, or m ade by SkinMedica, Inc., Allergan or any of their respective affiliates ( 1 ) prior to June 30, 2017, or ( 2 ) after June 30, 2017 that ( x ) is not covered by a Valid Cl aim of any Licensed Intellectual Property and ( y ) does not otherwise utilize or refe rence, and is not based on, any Licensed Intellectual Property . For the avoidance o f doubt, Exosome is not a to CCM for defining an ” -3- Confidential e. Section 1.8(a ) of the License Agreement shall be amended and restated in its entirety to read as follows : means ( i ) Products used to address any symptom or condition related to topical cosmetic ap plications, including without limitation, for enhancement of use of, or recovery from, microneedling, cosmetic wound healing, non - implantable device coating and t he signs, symptoms and appearance of aging skin, which Products are dispen sed, sold, distributed, supplied, marketed, commercialized, commercially exploited, m ade available or otherwise provided to customers ( including, without limitatio n, end users ) ( 1 ) through any website or digital platform, including Amazon.com, that is not a Luxury Platform and is not described in the definition of or ( 2 ) at any brick - and - mortar non - medical spa, salon or wellness center, e xcluding any brick - and - mortar business operated by any retailer included within t he definition of Luxury Platform and ( ii ) Products used in connection with, or deliv ered through equipment used to perform, Microdermabrasion, which products are disp ensed, sold, distributed, supplied, marketed, commercialized, commercially ex ploited, made available or otherwise provided to customers on any Luxury Platf orm . For clarity, Exclusive Field of Use does not include hair growth / care, non -cosmetic wound healing, implantable device coatings, orthopedics, oncology, cuticle / nail growth / care, muscle growth / regeneration / care, or dermal fillers . ” f. Section 1.27 of the License Agreement shall be a mended and restated in its entirety to read as follows : means any topical formulation including CCM and / o r Exosomes as ingredients . In no event shall include ( i ) any product in the SkinMedica product line existing as of June 30, 2017 or ( ii ) a ny Allergan product that does not include CCM or Exosomes as ingredients, including b ut not limited to future SkinMedica products . ” g. Section 1.32 of the License Agreement is hereby amended and restated in its entirety to read as follows : means ( i ) any technical, scientific and other dat a, information and know - how ( including, but not limite d to, any biological, chemical, pharmacological, toxicological, pharmaceutical, phy sical, analytical, pre - clinical, clinical, safety, manufacturing and quality control data and information, and further including, but not limited to, study designs and pr otocols, assays and biological methodology ) that ( a ) is described on Schedule B. ( b ) was or is used, created or developed either by or on behalf of [COMPANY], and r elates -4- Confidential directly to a Product in the Field of Use or ( c ) is at any time during the Term owned or otherwise Controlled by [COMPANY], whether existi ng as of the Effective Date or arising thereafter, and is necessary for the develo pment, use or manufacture of Products for the Field of Use and ( ii ) any and all Intellectual Property Rights embodied in or associated with any of the foregoing ; provided, however, that notwithstanding anything to the contrary, the Techn ical Information shall not include any Joint Patents or Joint Improvements nor shall i t include certain [COMPANY] core technical information necessary to manufacture CCM ( ) or certain [COMPANY] core technical in formation necessary to manufacture Exosomes ( ) .”h . The following section 1.38 is added to the License Agreement : means a procedure described variously as or ; i.e. : an aesthetic procedure in which the skin ( whe ther on the face or elsewhere on the body ) is treated with a topically applied technolog y designed to exfoliate and or remove dead epidermal cells . ” 4